Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 90OTHER 32NIH 3OTHER_GOV 2NETWORK 1INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 3Dermatologic 3Other solid neoplasm 2Gynecologic 2Sarcoma 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Advanced Solid Tumours 1Advanced Solid Tumor 1

Interventions

pembrolizumab 2fludarabine 2apatinib 2Interleukin-2 2Cyclophosphamide 2spartalizumab 1phosphorylethanolamine 1olaparib 1liposomal doxorubicin 1ivarmacitinib 1camrelizumab 1anlotinib 1Valproic Acid 1Topotecan 1Talc 1Pharmaceutical Services 1Injections 1Hydralazine 1Cisplatin 1Cerebral Decortication 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × pembrolizumab × Other solid neoplasm × Clear all
NCT05701527 2026-02-05

A Study of EBC-129 in Advanced Solid Tumours

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Phase 1 Recruiting
98 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown
100 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡